ATE132136T1 - Antitumor anthracenderivate - Google Patents
Antitumor anthracenderivateInfo
- Publication number
- ATE132136T1 ATE132136T1 AT92907670T AT92907670T ATE132136T1 AT E132136 T1 ATE132136 T1 AT E132136T1 AT 92907670 T AT92907670 T AT 92907670T AT 92907670 T AT92907670 T AT 92907670T AT E132136 T1 ATE132136 T1 AT E132136T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- nitrogen atom
- hydroxy
- group
- separately selected
- Prior art date
Links
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical class C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004990 dihydroxyalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
- C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
- C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919107843A GB9107843D0 (en) | 1991-04-12 | 1991-04-12 | Anti-cancer compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE132136T1 true ATE132136T1 (de) | 1996-01-15 |
Family
ID=10693185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92907670T ATE132136T1 (de) | 1991-04-12 | 1992-04-10 | Antitumor anthracenderivate |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5461078A (de) |
| EP (1) | EP0579646B1 (de) |
| JP (1) | JPH06506923A (de) |
| AT (1) | ATE132136T1 (de) |
| AU (1) | AU660883B2 (de) |
| CA (1) | CA2108256A1 (de) |
| DE (1) | DE69207182T2 (de) |
| ES (1) | ES2082461T3 (de) |
| GB (2) | GB9107843D0 (de) |
| WO (1) | WO1992018469A1 (de) |
| ZA (1) | ZA922641B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107852D0 (en) * | 1991-04-12 | 1991-05-29 | Patterson Laurence H | Anti-cancer compounds |
| EP1019385B1 (de) * | 1995-09-15 | 2004-01-14 | PHARMACIA & UPJOHN COMPANY | Aminoaryl oxazolidinone n-oxide |
| GB2333454B (en) * | 1998-03-26 | 2000-08-09 | Us Army | Substituted aromatic compounds for treatment of antibiotic resistant infections |
| RU2349311C1 (ru) * | 2007-08-02 | 2009-03-20 | Михаил Владимирович Кутушов | Применение дериватов нафталина в качестве средств для лечения онкологических заболеваний |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| CN107056623A (zh) * | 2017-05-02 | 2017-08-18 | 南京安琪儿生物科技有限公司 | 一种蓝色溶酶体标记荧光染料的合成新方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1118414A (fr) * | 1953-06-19 | 1956-06-06 | Yoshitomi Pharmaceutical | Procédé de préparation des nu-oxydes d'amines tertiaires aliphatiques halogénées |
| GB781237A (en) * | 1954-12-14 | 1957-08-14 | Sterling Drug Inc | Anthracene derivatives and their preparation |
| FR1316453A (fr) * | 1958-07-05 | 1963-02-01 | Parke Davis & Co | Procédé de fabrication de composés acridinylamino-o-crésol, 10-oxyde |
| US3174994A (en) * | 1962-01-30 | 1965-03-23 | Smith Kline French Lab | Hypocholesterolemic n-oxide compositions |
| FR1505351A (fr) * | 1966-01-06 | 1967-12-15 | Rhone Poulenc Sa | Nouveaux dérivés de l'anthracène et leur préparation |
| CH517096A (de) * | 1968-08-31 | 1971-12-31 | Starogardzkie Zakl Farma | Verfahren zur Herstellung neuer, biologisch aktiver 1-Nitro-9-(dialkyl-aminoalkylamino)-akridin-N10-oxide |
| IL69211A (en) * | 1982-07-23 | 1987-01-30 | Warner Lambert Co | Substituted anthra(1,9-cd)pyrazol-6(2h)-ones,their preparation and pharmaceutical compositions containing them |
| US4555572A (en) * | 1983-07-19 | 1985-11-26 | Warner-Lambert Company | Pyrazolo[3,4,5-kl]acridine compositions and methods for their production and use |
| US4626540A (en) * | 1983-11-08 | 1986-12-02 | Warner-Lambert Company | Substituted 1-amino-4-nitro-acridinones and methods of treating bacterial infections and leukemia with them |
| DE3405330A1 (de) * | 1984-02-15 | 1985-08-22 | Sandoz-Patent-GmbH, 7850 Lörrach | Neue allylamine, verfahren zu ihrer herstellung und ihre verwendung |
| US4686218A (en) * | 1985-01-30 | 1987-08-11 | Smithkline Beckman Corporation | Use of 6-chloro-3-methyl-1H-2,3,4,5-tetrahydro-3-benzazepine-n-oxide, as a prodrug |
| IN164921B (de) * | 1986-07-22 | 1989-07-08 | Hoechst India | |
| GB8923075D0 (en) * | 1989-10-13 | 1989-11-29 | Patterson Laurence H | Anti-cancer compounds |
| US4963554A (en) * | 1990-02-14 | 1990-10-16 | Ortho Pharmaceutical Corporation | 6,7-dimethoxy-1,2-dihydro-2-arylquinazoline-3-oxides |
-
1991
- 1991-04-12 GB GB919107843A patent/GB9107843D0/en active Pending
-
1992
- 1992-04-10 JP JP4507713A patent/JPH06506923A/ja active Pending
- 1992-04-10 GB GB9207957A patent/GB2254613B/en not_active Revoked
- 1992-04-10 US US08/133,033 patent/US5461078A/en not_active Expired - Fee Related
- 1992-04-10 AU AU15376/92A patent/AU660883B2/en not_active Ceased
- 1992-04-10 WO PCT/GB1992/000646 patent/WO1992018469A1/en not_active Ceased
- 1992-04-10 AT AT92907670T patent/ATE132136T1/de not_active IP Right Cessation
- 1992-04-10 DE DE69207182T patent/DE69207182T2/de not_active Expired - Fee Related
- 1992-04-10 EP EP92907670A patent/EP0579646B1/de not_active Expired - Lifetime
- 1992-04-10 ES ES92907670T patent/ES2082461T3/es not_active Expired - Lifetime
- 1992-04-10 CA CA002108256A patent/CA2108256A1/en not_active Abandoned
- 1992-04-10 ZA ZA922641A patent/ZA922641B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB9107843D0 (en) | 1991-05-29 |
| GB2254613A (en) | 1992-10-14 |
| GB2254613B (en) | 1995-01-25 |
| AU1537692A (en) | 1992-11-17 |
| ZA922641B (en) | 1993-10-11 |
| DE69207182D1 (en) | 1996-02-08 |
| US5461078A (en) | 1995-10-24 |
| GB9207957D0 (en) | 1992-05-27 |
| EP0579646B1 (de) | 1995-12-27 |
| WO1992018469A1 (en) | 1992-10-29 |
| EP0579646A1 (de) | 1994-01-26 |
| CA2108256A1 (en) | 1992-10-13 |
| ES2082461T3 (es) | 1996-03-16 |
| AU660883B2 (en) | 1995-07-06 |
| JPH06506923A (ja) | 1994-08-04 |
| DE69207182T2 (de) | 1996-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE101181T1 (de) | Anti-krebs-verbindungen. | |
| MY108261A (en) | Water soluble camptothecin derivatives | |
| PT1140851E (pt) | 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais | |
| KR950700278A (ko) | 벤조사이클로헵텐, 벤조옥세핀 및 벤조티에핀(benzocycloheptenes, benzoxepines and benzothiepines) | |
| ATE165095T1 (de) | Heterocyclische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| ATE132136T1 (de) | Antitumor anthracenderivate | |
| FI910303A0 (fi) | Derivat av tiazolidin med blodtrycksnedsaenkande effekt och terapeutisk anvaendning av dessa. | |
| TW333532B (en) | Benzopyrans | |
| DK379888A (da) | 1,2-benzisoxazol- og 1,2-benzisothiazol-derivater | |
| ES2120039T3 (es) | Nuevos acildipeptidos heterociclicos, procedimientos de preparacion y composiciones farmaceuticas que los contienen. | |
| MX9800925A (es) | Uso de derivados de adamantano para tratar enfermedades del oido interno. | |
| UA40569C2 (uk) | Похідні метилпіперазиназепіну, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |